Equities
  • Price (EUR)0.963
  • Today's Change-0.014 / -1.43%
  • Shares traded0.00
  • 1 Year change-32.28%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oriola Oyj, formerly known as Oriola-KD Corporation Oyj, is a Finland-based company active in the pharmaceutical sector. The Company is engaged in the retail and wholesale of pharmaceuticals, acting as a channel between pharmaceutical manufacturers and consumers, primarily in Finland and Sweden. The Company's reporting segments are Consumer, Services, and Healthcare. Through its own pharmacies, the Company provides consumers with not only medicines and pharmaceutical advice but also a selection of healthcare consumer products and customer service. The Company is active through a number of subsidiaries located throughout Europe, including PharmaService OY, Oriola AB, Oriola Oyj, Farenta Oy, Kronans Droghandel Apotek AB and Svensk dos AB.

  • Revenue in EUR (TTM)1.49bn
  • Net income in EUR-20.70m
  • Incorporated2006
  • Employees801.00
  • Location
    Oriola OyjOrionintie 5ESPOO 02200FinlandFIN
  • Phone+358 1042999
  • Fax+358 104294300
  • Websitehttps://www.oriola.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.